An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

The Republican-led Senate rescued funding for PEPFAR in a package of spending cuts last month, but the HIV-prevention program ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Announced at the International AIDS Society (IAS) 2025 conference taking place from 13-17 July in Kigali, Rwanda, MSD has launched two Phase III trials, EXPrESSIVE-10 and EXPrESSIVE-11, which will ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

The UNAIDS annual report warns that Trump-era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...